Trading Doubled

MSc Comp Sci, learning on the go

[Trading Doubled @TradingDoubles1]

@bio_tracker2026 @financebully @bioadvo Yeah reply to this example @financebully, you cant just avoid him by saying “let’s see what FDA does” after calling him out for initially avoiding your question lmao

[Trading Doubled @TradingDoubles1]

Think we see $130+ tomorrow $ABVX, just sucks this sort of presentation should’ve happened on the first day of maintenance, stock would’ve been at $150+

[Trading Doubled @TradingDoubles1]

So this was the real maintenance data release, it’s like night and day $ABVX

[Trading Doubled @TradingDoubles1]

@RudyResearch Yall need to stop scaring me

[Trading Doubled @TradingDoubles1]

@Taintslapp12283 Yeah this is phishy, seems like data is out there now

[Trading Doubled @TradingDoubles1]

@JoseRestonVA @pawcio2009 On a side note Jose, are you back in Abivax? Or won’t be touching it for now?

[Trading Doubled @TradingDoubles1]

@financebully @mickeychiku Any recent biotechs that have done something like this, besides ABVX?

[Trading Doubled @TradingDoubles1]

@Taintslapp12283 @meremrtl is gonna flex on us at the end of the day, isn’t he?

[Trading Doubled @TradingDoubles1]

@financebully @mickeychiku Not sure why them updating and adding clarity to results would be worrisome, just seems like you’re being nit picky here. Can they even do anything to add color? Are they supposed to be silent in your eyes from now on?

[Trading Doubled @TradingDoubles1]

@GermanBiotech @RNAiAnalyst @princetongb Hey GB, did you get a chance to look at ABVX’s “silent” update to their presentation deck on their website, specifically related to the added info on malignancies?

Just wondering if you had any insights there, or if that moved the noodle for yourself on the drug.

[Trading Doubled @TradingDoubles1]

@basadomente This is brilliant, thank you for sharing.

[Trading Doubled @TradingDoubles1]

@financebully Gotcha. Is there space for optics to materially improve if the safety data is squeaky clean released later this month in your pov?

[Trading Doubled @TradingDoubles1]

@financebully Are you in the M&A space? Just curious why optics matter, or atleast why it would matter as much as data from the actual trials of this drug.

[Trading Doubled @TradingDoubles1]

@financebully I don’t think potential strategic buyers are concerned with optics but rather with nuanced data, but we will see in due time.

[Trading Doubled @TradingDoubles1]

@financebully Are you still bullish after the release of maintenance data? Do you think there’s merit to differentiate the malignancies we’re seeing in the 50mg arm, or are you of the mind that the 6-7 cases represent a true signal for malignancy?

[Trading Doubled @TradingDoubles1]

@financebully @dumjgr88 You said you were long ABVX, is it fair to say you don’t think the drug at the higher dosage is causing a wide set of malignancies? Just want to clarify what you thought instead of you playing devil’s advocate

[Trading Doubled @TradingDoubles1]

@charlie_lees Hey Professor, just wanted to know if you had any further thoughts on the recent maintenance data dump from this company regarding the drug, especially regarding malignancies. Thank you!

[Trading Doubled @TradingDoubles1]

@BertrandBio Hello Bertrand. Just wanted to thank you for this insight into your journey with this investment. Also wanted to ask if you had any further thoughts on the recent case of malignancies in the maintenance data. Thank you.

[Trading Doubled @TradingDoubles1]

@TonyFauci2 @seedy19tron Even if this is a potential blind spot for abivax, isn’t it still too fast for anyone to develop malignancies in 44ish weeks trial period?